brukinsa
Brukinsa (Zanubrutinib) is a kinase inhibitor used to treat Mantle-Cell Lymphoma.
Zanubrutinib · by Beone Medicines USA
Key facts
- Active ingredient
- Zanubrutinib
- Drug class
- Kinase Inhibitor
- Form
- Capsule, Tablet
- Strength
- Zanubrutinib 160MG · Zanubrutinib 80MG
- Type
- Prescription (Rx)
- Brand or generic
- Brand-name
- May treat
- mantle-cell lymphoma
- Manufacturer
- Beone Medicines USA
- FDA application
- NDA218785
Drug class
How this class works, per Tyrosine Kinase Inhibitors - StatPearls - NCBI Bookshelf.
May treat (source: NIH RxClass)
See how Brukinsa ranks — best-rated kinase inhibitor for:
Dosage forms
Capsule and Tablet
The forms currently marketed in the U.S., per the FDA National Drug Code Directory.
Ways to save
Ask for the generic
Same active ingredient, far cheaper. Is there a generic? →
Request a 90-day supply
Bulk fills usually lower the per-dose price vs monthly refills.
Use copay cards
Manufacturer copay cards & patient-assistance programs — especially for brand drugs.
Compare alternatives
A same-class option may cost less. See alternatives →
Frequently asked questions
- What does Brukinsa treat?
- Brukinsa (Zanubrutinib) may be used to treat mantle-cell lymphoma, based on NIH RxClass drug-classification data (conditions a drug may treat — not a verbatim copy of the FDA-approved label). This is general reference, not medical advice.
- How does Brukinsa work?
- Brukinsa is a kinase inhibitor. Kinase inhibitors block protein kinases, the enzymes that relay 'grow and divide' signals inside cells. By shutting down the overactive kinase signals that a tumor depends on, they help slow or stop cancer cells from multiplying.
- Is there a coupon or discount for Brukinsa?
- pharmaranks is an independent ratings site, not a pharmacy — we don't issue coupons or sell Brukinsa. To pay less, ask your prescriber or pharmacist whether a generic equivalent exists, check the manufacturer's copay/savings card and patient-assistance program, and compare a pharmacy discount card against your insurance copay. Prices vary by pharmacy, insurance, and location, so always confirm at the counter. This is general reference, not medical or financial advice.
- Who makes Brukinsa?
- Brukinsa is marketed by Beone Medicines USA. You can see Beone Medicines USA's full profile, rating, and other products on pharmaranks.
- Is Brukinsa a brand-name or generic drug?
- Brukinsa is a brand-name product with the active ingredient Zanubrutinib.
- Is Brukinsa available over the counter?
- No. Brukinsa is a prescription (Rx) medication in the US — you need a prescription from a licensed clinician (in person or via telehealth); it isn't sold over the counter. For some conditions there are OTC alternatives — ask your pharmacist.
- What forms does Brukinsa come in?
- Brukinsa is currently marketed as capsule and tablet, per the FDA's National Drug Code Directory.
- What class of drug is Brukinsa?
- Brukinsa is classified as kinase inhibitor, per the FDA's Established Pharmacologic Class.
- Is Brukinsa FDA-registered?
- Brukinsa is on record with the U.S. FDA under application number NDA218785. You can verify this on its official FDA label.
Information is sourced from public FDA regulatory data. Provided for general reference only — not medical advice. Always consult a licensed professional and the current prescribing information.
What people report to the FDA about ZANUBRUTINIB
The FDA Adverse Event Reporting System (FAERS) collects reports from patients and clinicians. It holds 847 reports naming ZANUBRUTINIB — the active ingredient in Brukinsa, and the FDA flagged 93% of those reports as serious. The effects reported most often — leaving out reports about overdose, misuse or the condition being treated, which dominate the raw list for common medicines:
- anaemia139 reports
- white blood cell count decreased104 reports
- platelet count decreased96 reports
- neutrophil count decreased93 reports
- pneumonia92 reports
- myelosuppression82 reports
- lymphocyte count decreased79 reports
- cytokine release syndrome76 reports
Read these as a signal, not a rate. A report does not mean ZANUBRUTINIB caused the effect — anyone can file one, and many describe people taking several medicines for several conditions. Crucially there is no denominator: FAERS does not record how many people took the drug, so these counts cannot be turned into “X% of patients” — a bigger number often just means a more widely used or more talked-about drug. Duplicates exist, and publicity drives reporting. For what is actually established, read the FDA label.
Source: openFDA drug/event (FAERS), retrieved September 26, 2026.
Reviews
No reviews yet. Be the first to write one.
People also viewed
danziten
Nilotinib Tartrate
everolimus
Everolimus
ofev
Nintedanib Esylate
sprycel
Dasatinib
afinitor
Everolimus
calquence
Acalabrutinib
Compare Brukinsa head-to-head
More kinase inhibitor drugs
Browse medications A–Z
Research products from A to Z, compare independent ratings, and find alternatives.
brukinsa
New